Safety Monitoring and Contraindications for Nexlizet (Ezetimibe 10 mg / Rosuvastatin)

Hepatic Monitoring

• Baseline liver panel (ALT, AST, alkaline phosphatase, total bilirubin) should be obtained before starting Nexlizet – American College of Cardiology recommendation. 1
• During therapy, hepatic transaminases must be re‑checked according to standard statin monitoring schedules – American College of Cardiology. 1

• Consecutive elevations of transaminases ≥ 3 × upper‑limit of normal occur in 1.3 % of patients receiving ezetimibe + statin versus 0.4 % with statin alone – Praxis Medical Insights.

  Treatment group	≥ 3 × ULN transaminase incidence
  Ezetimibe + statin	1.3 %
  Statin alone	0.4 %

  2

• Nexlizet is contraindicated in patients with moderate or severe hepatic impairment – American College of Cardiology. 1

Muscle Toxicity Surveillance

• Myopathy and rhabdomyolysis have been reported with ezetimibe alone or combined with statins – American College of Cardiology. 1
• Patients should be instructed to report any unexplained muscle pain, tenderness, or weakness, especially during the first few months of therapy – American College of Cardiology; Praxis Medical Insights. [1][2]
• If muscle symptoms develop, rigorous physical activity should be avoided – Clinical Infectious Diseases guideline. 3

Pregnancy, Lactation, and Pre‑conception Counseling

• All lipid‑lowering agents, including ezetimibe and rosuvastatin, are contraindicated during pregnancy and breastfeeding – Praxis Medical Insights. 4
• Women using lipid‑lowering therapy for primary prevention should stop the medication at least 1 month (preferably 3 months) before attempting conception, and immediately if pregnancy is confirmed – Praxis Medical Insights. 4
• There are no human safety data for ezetimibe use in pregnancy – American College of Cardiology. 1
• Pre‑conception counseling is recommended for women of child‑bearing age on lipid‑lowering therapy – Praxis Medical Insights. 4
• Bile‑acid sequestrants are the only lipid‑lowering drugs approved for use during pregnancy when treatment is absolutely necessary – Praxis Medical Insights. 4

High‑Risk Drug Interactions

• Cyclosporine co‑administration raises ezetimibe exposure and modestly alters cyclosporine levels; cyclosporine concentrations should be monitored – American College of Cardiology. 1
• Gemfibrozil increases ezetimibe bioavailability, though the clinical impact is considered minor – American College of Cardiology. 1
• Bile‑acid sequestrants (e.g., cholestyramine) markedly reduce ezetimibe absorption; ezetimibe should be taken ≥ 2 h before or ≥ 4 h after such agents – American College of Cardiology. 1

Common Adverse Effects to Monitor

• Ezetimibe monotherapy may cause upper‑respiratory‑tract infection, diarrhea, arthralgia, sinusitis, and extremity pain – American College of Cardiology. 1
• When combined with rosuvastatin, ezetimibe is associated with nasopharyngitis, myalgia, upper‑respiratory‑tract infection, arthralgia, and diarrhea – American College of Cardiology. 1

Clinical Pitfalls to Avoid

• Do not continue Nexlizet in women planning pregnancy without a thorough risk‑benefit discussion – Praxis Medical Insights. 4
• Unexplained muscle symptoms must be evaluated promptly and may require discontinuation of therapy – American College of Cardiology; Praxis Medical Insights. [1][2]
• Nexlizet must not be prescribed to patients with moderate‑to‑severe hepatic impairment – American College of Cardiology. 1
• Ezetimibe should never be taken simultaneously with bile‑acid sequestrants; separate dosing by at least 2–4 hours – American College of Cardiology. 1